^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCND1 overexpression

i
Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
Entrez ID:
Related biomarkers:
1d
Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo. (PubMed, Mol Biol Rep)
In HPV-negative HNSCC, CDK4/6 inhibitor shows promising anti-tumor effects, which exhibits a synergistic effect when combined with EGFR inhibitor only in specific drug concentration and mouse model.
Preclinical • Journal
|
CCND1 (Cyclin D1) • MMP9 (Matrix metallopeptidase 9)
|
CCND1 overexpression
|
Erbitux (cetuximab) • cisplatin • Ibrance (palbociclib)
11d
CAPITAL: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Jun 2024
Trial completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Truqap (capivasertib)
11d
The oncogene cyclin D1 promotes bipolar spindle integrity under compressive force. (PubMed, PLoS One)
However, it also protects spindle poles from fracturing under compressive force, a deleterious outcome linked to multipolar cell divisions. Our findings suggest that cyclin D1 overexpression may adapt cells to increased compressive stress, possibly contributing to its prevalence in cancers such as breast cancer by allowing continued proliferation in mechanically challenging environments.
Journal
|
CCND1 (Cyclin D1)
|
CCND1 overexpression
14d
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (clinicaltrials.gov)
P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV
17d
A Case Report of Metastatic Breast Cancer with Peritoneal Metastasis and Massive Ascites Responding to CDK4/6 Inhibitor(Palbociclib) (PubMed, Gan To Kagaku Ryoho)
The large amount of ascites decreased after the start of administration of fulvestrant and CDK4/6 inhibitor(PAL). Fifty months later, she continues to do good ADL and PR status. We experienced a case of metastatic breast cancer with massive ascites and peritoneal metastasis that was successfully treated with a CDK4/6 inhibitor(PAL)and achieved long- term survival.
Journal • Metastases
|
CCND1 (Cyclin D1)
|
CCND1 overexpression • CDKN2A negative • CCND1 expression
|
Ibrance (palbociclib) • fulvestrant
28d
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma. (PubMed, Oncology (Williston Park))
At the Lymphoma Research Foundation's 20th MCL Scientific Consortium and Workshop, researchers gathered to discuss recent developments in both basic scientific and clinical research to continue to develop an understanding of MCL and improve outcomes for patients. This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.
Journal
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression
1m
Circ-RNF111 Promotes Proliferation of Ovarian Cancer Cell SKOV-3 by Targeting the MiR-556-5p/CCND1 Axis. (PubMed, Biochem Genet)
In summary, circ-RNF111 promotes the proliferation of SKOV-3 cells by targeting the miR-556-5p/CCND1 axis. Circ-RNF111 may serve as a potential target for ovarian cancer therapy.
Journal
|
CCND1 (Cyclin D1)
|
CCND1 overexpression • CCND1 expression
1m
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (clinicaltrials.gov)
P1/2, N=33, Recruiting, Han weidong | Trial primary completion date: Dec 2023 --> Dec 2024
Trial primary completion date • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • decitabine • fludarabine IV
1m
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
P2, N=15, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr t(11;14) • CCND1 overexpression
|
Copiktra (duvelisib) • ETP-47187
2ms
ALTAMIRA: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=81, Active, not recruiting, Nordic Lymphoma Group | Recruiting --> Active, not recruiting
Enrollment closed
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Calquence (acalabrutinib)
2ms
The overexpression of cyclin D1 is a positive prognostic factor in advanced-stage breast carcinoma cases. (PubMed, North Clin Istanb)
Our results suggest that CDDN1 expression can be used as a potentially appropriate positive prognostic biomarker for advanced-stage BC cases.
Journal • Metastases
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
|
CCND1 overexpression
2ms
ACE-LY-004: An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=124, Active, not recruiting, Acerta Pharma BV | Trial completion date: Dec 2025 --> Sep 2026
Trial completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib)
2ms
V-MIND: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=100, Recruiting, Academic and Community Cancer Research United | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
CD19 (CD19 Molecule) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)
2ms
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Calquence (acalabrutinib)
2ms
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Calquence (acalabrutinib)
2ms
Enrollment open • Combination therapy
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
3ms
Trial completion date • Trial primary completion date • Adverse events • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
3ms
Reduction of HIF-1α/PD-L1 by Catalytic Topoisomerase Inhibitor Induces Cell Death Through Caspase Activation in Cancer Cells Under Hypoxia. (PubMed, Anticancer Res)
3EE,20Ac-ingenol induces an intricate interplay between P53 and HIF-1α accumulation via ATR activation that results in a high P53 accumulation, which promoted transient expression and early disappearance of HIF-1α, accelerating cell death. Strong P53 accumulation and consequent phosphatase and tensin homolog deleted on chromosome 10 activation in Panc-1 cells also reduced HIF-1α accumulation and programmed death-ligand 1 expression, which resulted in intense apoptosis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PTEN (Phosphatase and tensin homolog) • CCND1 (Cyclin D1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ATR (Ataxia telangiectasia and Rad3-related protein)
|
PD-L1 expression • CCND1 overexpression • HIF1A expression
3ms
NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Combination therapy
|
CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Chr t(11;14) • CCND1 overexpression
|
Imbruvica (ibrutinib) • pevonedistat (MLN4924)
3ms
Cyclin D1 extensively reprograms metabolism to support biosynthetic pathways in hepatocytes. (PubMed, J Biol Chem)
Pharmacologic inhibition of Cdk4 along with the downstream pyrimidine synthesis enzyme dihydroorotate dehydrogenase synergistically inhibits proliferation and survival of hepatocellular carcinoma cells. These studies demonstrate that cyclin D1 promotes a broad network of biosynthetic pathways in hepatocytes, and this model may provide insights into potential metabolic vulnerabilities in cancer cells.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
|
CCND1 overexpression
|
Ibrance (palbociclib) • orludodstat (BAY2402234)
3ms
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
CCND1 overexpression • CCND1 expression • CCND1-H
|
cisplatin • docetaxel • 5-fluorouracil
3ms
CAPITAL: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Aug 2023
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Truqap (capivasertib)
3ms
topMIND: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1/2, N=54, Active, not recruiting, Incyte Corporation | Phase classification: P1b/2a --> P1/2 | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024
Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Pan tumor
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
|
parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
3ms
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P1/2, N=23, Suspended, City of Hope Medical Center | Trial completion date: Dec 2023 --> Nov 2024 | Recruiting --> Suspended | Trial primary completion date: Dec 2023 --> Nov 2024
Trial completion date • Trial suspension • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • PAX5 overexpression
|
Venclexta (venetoclax) • Aliqopa (copanlisib)
4ms
A genetic variant in gene NDUFAF4 confers the risk of non-small cell lung cancer by perturbing hsa-miR-215 binding. (PubMed, Mol Carcinog)
Moreover, the overexpression of CCND1 could partially attenuate the effects of NDUFAF4 knock down on lung cancer cell migration and apoptosis, indicating that CCND1 may be involved in the tumor-promoting effects of NDUFAF4 as a downstream molecule of NDUFAF4 gene. In conclusion, the genetic variant rs1854268 (A > T) on NDUFAF4 confers NSCLC susceptibility by altering the binding affinity of hsa-miR-215-5p, thus regulating the expression of NDUFAF4 and subsequently influencing downstream tumor molecules and pathways such as CCND1, NF kappa B, and PI3K-AKT signaling pathways.
Journal
|
CCND1 (Cyclin D1) • AFF1 (AF4/FMR2 Family Member 1) • MIR215 (MicroRNA 215)
|
CCND1 overexpression
4ms
Immunohistochemical expression of E-Cadherin and Cyclin D1 in different grades of oral squamous cell carcinoma. (PubMed, J Oral Maxillofac Pathol)
The study revealed a good prognostic role of both E-Cadherin and Cyclin D1 in OSCC. The markers can be used for prognostic as well as therapeutic purposes.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDH1 (Cadherin 1) • CDK6 (Cyclin-dependent kinase 6)
|
CCND1 overexpression • CCND1 expression • CDH1 expression
4ms
Mutant N- and K-Ras Show Distinct Effects on Growth, Signaling and Drug Response in CRISPR-Cas Edited Alleles of a Myeloma Cell Line (ASH 2023)
We are currently testing new pan-Ras inhibitors to determine if there are distinct responses between our N- and K-ras edited cells, and we are expanding testing to a wider panel of myeloma cell lines containing ras mutations in the context of other genetic abnormalities. Details of gene expression distinctions, pathways, and drug responses that distinguish mutNras and mutKras in myeloma will be presented.
Preclinical
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1)
|
KRAS mutation • NRAS mutation • RAS mutation • NRAS wild-type • CCND1 overexpression • CCND1 expression • CCND1-H • KRAS expression
4ms
Upregulated TC1 and downregulated Chibby were correlated with the aberrant β-catenin expression in laryngeal squamous cell carcinoma. (PubMed, Medicine (Baltimore))
No association was found between overall survival and the expression of TC1, Chibby, and β-catenin (P > .05). The upregulated expression of TC1 and downregulated expression of Chibby were correlated with the aberrant expression of β-catenin and the high expression of Cyclin D1 and MMP-7 in LSCC tissues.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MMP7 (Matrix metallopeptidase 7)
|
MYC expression • CCND1 overexpression • CCND1 expression
4ms
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators. (PubMed, Target Oncol)
We conclude that perturbation in cell-cycle regulators leads to intrinsic osimertinib resistance and worse patient outcomes.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1)
|
EGFR mutation • CCND1 overexpression • CCND1 expression
|
Tagrisso (osimertinib) • Verzenio (abemaciclib)
4ms
NEIL3 promotes cell proliferation of ccRCC via the cyclin D1-Rb-E2F1 feedback loop regulation. (PubMed, DNA Repair (Amst))
In addition, there was a positive correlation between NEIL3 and E2F1 expression in clinical specimens of ccRCC. Taken together, our results suggest that NEIL3 serves as a proto-oncogene in ccRCC and presents as a novel candidate for ccRCC diagnosis and treatment.
Journal
|
CCND1 (Cyclin D1) • NEIL3 (Nei Like DNA Glycosylase 3) • E2F1 (E2F transcription factor 1)
|
CCND1 overexpression
4ms
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=12, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2023 --> Sep 2025
Trial completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy)
5ms
Phase classification • Adverse events • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
5ms
Phase Ib Clinical Study of Keynatinib (clinicaltrials.gov)
P1, N=75, Recruiting, Medolution Ltd. | Trial completion date: Apr 2024 --> Apr 2028 | Trial primary completion date: Oct 2023 --> Oct 2027
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
CCND1 overexpression • CCND1 expression • CCND1-H
|
keynatinib (TL007)
5ms
Evaluating the role of CDK4/6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancer (SABCS 2023)
We demonstrate STAT3 activation in a mouse model of HER2 driven breast cancer and show persistent activation in recurrent tumors lacking HER2 expression rendering them resistant to HER2-targeted therapy. We also demonstrate the anti-tumor effect of palbociclib in primary tumors with HER2-dependent proliferation. Taken together, our findings suggest that pSTAT3 is a viable therapeutic target and provides the rationale for combination therapy with CDK4/6 inhibition using palbociclib and STAT3 inhibition with a novel STAT3 inhibitor in HER2-positive breast cancer.
Preclinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
HER-2 positive • HR positive • HER-2 overexpression • HER-2 expression • MET overexpression • CCND1 overexpression • ER expression • STAT3 overexpression
|
Ibrance (palbociclib)
5ms
The Novel CDK9/CDK4/6/PI3K Triple Inhibitor LCI139 for the Treatment of MYC-Driven Mantle Cell Lymphoma (ASH 2023)
Compared with clinical single agent CDK9 inhibitor AZD4573, LCI139 is less toxic to normal human stromal cells (HS-5), whereas both LCI139 and AZD4573 have no significant cytotoxic effect on normal human foreskin fibroblast cells (Hs68). Finally, we show that LCI139 overcomes chronic ibrutinib resistance by decreasing viability in JeKO-1 IR and Mino IR cells with an IC50 of 79 nM and 89 nM, respectively. Therefore, the multitarget small molecule inhibitor LCI139 has superior potency against IR MCL cell lines and overcomes ibrutinib-resistance at nanomolar doses.
PARP Biomarker
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CDK9 (Cyclin Dependent Kinase 9) • ANXA5 (Annexin A5)
|
MYC expression • CCND1 overexpression
|
Imbruvica (ibrutinib) • AZD4573
5ms
Mutant N- and K-Ras Show Distinct Effects on Growth, Signaling and Drug Response in CRISPR-Cas Edited Alleles of a Myeloma Cell Line (ASH 2023)
We are currently testing new pan-Ras inhibitors to determine if there are distinct responses between our N- and K-ras edited cells, and we are expanding testing to a wider panel of myeloma cell lines containing ras mutations in the context of other genetic abnormalities. Details of gene expression distinctions, pathways, and drug responses that distinguish mutNras and mutKras in myeloma will be presented.
Preclinical
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1)
|
KRAS mutation • NRAS mutation • RAS mutation • NRAS wild-type • CCND1 overexpression • CCND1 expression • CCND1-H • KRAS expression
5ms
Prognostic Significance of Cyclin D1 Expression in Small Intestinal Adenocarcinoma. (PubMed, Cancers (Basel))
In conclusion, cyclin D1 was commonly overexpressed in SIACs, and cyclin D1 acted as a favorable prognostic indicator in patients with SIACs. These findings in SIACs may, thus, be important to further comprehend the mechanism of cyclin D1 in carcinogenesis and to strategize appropriate patient therapies.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • CCND1 (Cyclin D1)
|
KRAS mutation • CCND1 overexpression • CCND1 expression
5ms
New P3 trial
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression
|
Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
6ms
ZEBRA: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=50, Not yet recruiting, University College, London | Trial completion date: Dec 2027 --> Oct 2028 | Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Nov 2027 --> Oct 2028
Trial completion date • Trial initiation date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
6ms
TrAVeRse: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=100, Not yet recruiting, AstraZeneca | Trial completion date: May 2028 --> Feb 2029 | Trial primary completion date: May 2028 --> Feb 2029
Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
|
Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
6ms
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) (clinicaltrials.gov)
P3, N=352, Active, not recruiting, Pharmacyclics LLC. | Trial completion date: Sep 2023 --> Nov 2024 | Trial primary completion date: Sep 2023 --> Nov 2024
Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
|
TP53 mutation • Chr t(11;14) • CCND1 overexpression • PAX5 overexpression
|
Venclexta (venetoclax) • Imbruvica (ibrutinib)